Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab in locally advanced GEJ adenocarcinoma
NCT05918419Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in adenocarcinoma of the gastroesophageal junction, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
serplulimab
03
Conditions
adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT05918419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918419.